Category: Research
C5aR1 promotes invasion, metastasis, and poor prognosis in cSCC
Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer, and the metastatic from is associated with a poor prognosis. Here, the role of the complement C5a receptor C5aR1 was…
Read more about 'C5aR1 promotes invasion, metastasis, and poor prognosis in cSCC'...
Cancer vaccine trials in advanced melanoma show promising efficacy
Background: The emergence of checkpoint inhibitors (CPIs) has significantly improved survival outcomes in later-stage melanoma. However, the efficacy of these treatments remains limited, with around …
Read more about 'Cancer vaccine trials in advanced melanoma show promising efficacy'...
Evaluation of nivolumab and ipilimumab for the treatment of resectable stage III melanoma: Improved outlook for patients with Stage III melanoma
Introduction: Twenty years ago, surgery was the centerpiece of treatment for cutaneous melanoma, including for resectable stage III and IV patients. The arrival of effective systemic therapies in the…
Clinicopathologic gene expression profile (CP-GEP) model can reduce number of unnecessary SLNBs performed
Context & aim: Sentinel lymph node biopsy (SLNB) is an invasive procedure that detects microscopic nodal metastasis, crucial for accurate staging and optimal management. In melanoma, most patients wh…
Outcomes of pembrolizumab in advanced melanoma by age and sex
Background: Immune checkpoint inhibitors are standard treatment for advanced melanoma. Pembrolizumab (programmed cell death-1 inhibitor) monotherapy is recommended as first-line treatment. However, r…
Read more about 'Outcomes of pembrolizumab in advanced melanoma by age and sex'...
Clinical perspective on the current burden of melanoma overdiagnosis and its future value for progress in the field of melanoma
Overdiagnosis in melanoma is a nuanced and evolutionary issue. It may appear to be an epidemic from an epidemiological point of view; however, it is important to appreciate all perspectives. We consid…
Phase 1b study of tovorafenib, plozalizumab or vedolizumab plus standard-of-care immune checkpoint inhibitors in patients with advanced melanoma
Background: Novel advanced melanoma therapy combinations may increase treatment efficacy and reduce treatment-related toxicities. Methods: This open-label, nonrandomized, multicenter, phase 1b, 3-a…
Upskilling primary care nurses working in regional Australia in skin cancer prevention education and early detection provides innovative solution to meet screening needs of high-risk individuals
Background: Early detection of skin cancer is critical for improved health outcomes. Many Australians living in regional and rural areas are at an increased risk of skin cancer yet face significant b…
Serum metabolome serves as diagnostic biomarker and discriminates patients with melanoma from healthy individuals
Melanoma is a deadly cancer with increasing incidence and mortality rates, and biomarkers for diagnosis are urgently needed. The impact of the microbiome, genetic factors, and immunologic markers on d…
Review of immune checkpoint inhibitors in non-melanoma malignancies
Over the last decade, immune checkpoint inhibitors (ICIs) have been established as an integral component of the contemporary anticancer armamentarium. In dermatology, ICIs are most established as trea…
Read more about 'Review of immune checkpoint inhibitors in non-melanoma malignancies'...